{"entity":{"id":"plexium","kind":"company","name":"Plexium","aka":[],"tldr":"Plexium makes single-piece pills that make cancer cells destroy specific proteins. Its lead drug removes a protein called SMARCA2 in tumours that have lost its partner SMARCA4, and is in an early human trial.","summary":"Plexium is a San Diego clinical-stage targeted protein degradation company that rationally designs monovalent direct degraders and molecular glues using its DELTA Discovery platform. PLX-61639 is an oral SMARCA2-selective direct degrader using a tissue-restricted E3 ligase, in a phase 1 trial in SMARCA4-mutant advanced solid tumours, exploiting SMARCA2/SMARCA4 synthetic lethality. PLX-4545 is an oral cereblon-based IKZF2 molecular glue degrader intended to convert regulatory T cells into effector-like cells and improve checkpoint inhibitor responses; it has completed a healthy-volunteer study. PLX-66140 is a preclinical CDK2 glue degrader for ER-positive/HER2-negative breast cancer and CCNE1-amplified tumours. Investors shown on the company site include The Column Group, TCG X, SoftBank, DCVC Bio, BVF Partners and Lux Capital; a Form D filed in August 2025 reports 60.1 million US dollars sold.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://plexium.com/"},{"label":"Pipeline","url":"https://plexium.com/pipeline/"},{"label":"Clinical trials","url":"https://plexium.com/clinical-trials/"},{"label":"Form D (August 2025)","url":"https://www.sec.gov/Archives/edgar/data/2082715/000208271525000001/primary_doc.xml"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":["targeted-therapy"],"technologies":["protac-degrader","synthetic-lethality-approaches"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not sourced."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://plexium.com/","stage":"growth","investors":[],"funding":[{"round":"Form D offering","year":2025,"amountUsd":60115703,"source":"https://www.sec.gov/Archives/edgar/data/2082715/000208271525000001/primary_doc.xml","note":"Total sold per Form D filed August 2025; first sale July 2025"}]},"route":"/companies/plexium/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}]}}